We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.43%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$956M
AUM Growth
+$110M
Cap. Flow
+$88M
Cap. Flow %
9.21%
Top 10 Hldgs %
34.18%
Holding
136
New
4
Increased
63
Reduced
26
Closed
5

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$10.5M
2
ALGN icon
Align Technology
ALGN
+$9.68M
3
CELG
Celgene Corp
CELG
+$9.59M
4
ELV icon
Elevance Health
ELV
+$9.1M
5
COR icon
Cencora
COR
+$7.21M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$7.35M
2
CI icon
Cigna
CI
+$4.96M
3
BCR
CR Bard Inc.
BCR
+$4.65M
4
CNC icon
Centene
CNC
+$4.38M
5
ALKS icon
Alkermes
ALKS
+$4.36M

Sector Composition

Rank Sector Weight
1 Healthcare 94.19%
2 Financials 0.94%
3 Industrials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
76
DELISTED
Seagen Inc. Common Stock
SGEN
$2.45M 0.26%
45,000
+6,000
+15% +$307K
PRTA icon
77
Prothena Corp
PRTA
$455M
$2.42M 0.25%
37,400
-3,600
-9% -$221K
RARE icon
78
Ultragenyx Pharmaceutical
RARE
$2.89B
$2.24M 0.23%
42,000
– –
DXCM icon
79
DexCom
DXCM
$29.5B
$2.2M 0.23%
180,000
+30,000
+20% +$530K
HCSG icon
80
Healthcare Services Group
HCSG
$1.74B
$2.05M 0.21%
38,000
+1,500
+4% +$77.1K
QGEN icon
81
Qiagen
QGEN
$8.43B
$1.94M 0.2%
58,103
-16,817
-22% -$579K
JUNO
82
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.93M 0.2%
43,000
– –
CYTO
83
DELISTED
Altamira Therapeutics Ltd
CYTO
$1.78M 0.19%
27
– –
IPXL
84
DELISTED
Impax Laboratories, Inc.
IPXL
$1.77M 0.18%
87,000
-88,000
-50% -$1.68M
MRK icon
85
Merck
MRK
$312B
$1.76M 0.18%
28,820
– –
HCM icon
86
HUTCHMED
HCM
$1.92B
$1.75M 0.18%
64,573
+35,331
+121% +$867K
ANGO icon
87
AngioDynamics
ANGO
$549M
$1.74M 0.18%
101,700
– –
IRTC icon
88
iRhythm Holdings
IRTC
$3.63B
$1.73M 0.18%
33,400
+9,900
+42% +$448K
PTLA
89
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.7M 0.18%
31,500
-4,500
-13% -$264K
HCA icon
90
HCA Healthcare
HCA
$82.2B
$1.7M 0.18%
21,300
– –
GMED icon
91
Globus Medical
GMED
$10.4B
$1.64M 0.17%
55,000
+15,000
+38% +$458K
TDOC icon
92
Teladoc Health
TDOC
$1.7B
$1.56M 0.16%
47,000
+24,500
+109% +$803K
CLVS
93
DELISTED
Clovis Oncology, Inc.
CLVS
$1.52M 0.16%
18,500
– –
HALO icon
94
Halozyme
HALO
$9.22B
$1.52M 0.16%
87,600
-131,400
-60% -$1.78M
PEN icon
95
Penumbra
PEN
$12.5B
$1.52M 0.16%
16,800
+5,500
+49% +$474K
TRHC
96
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$1.48M 0.16%
55,407
+18,500
+50% +$353K
ACHC icon
97
Acadia Healthcare
ACHC
$3.14B
$1.48M 0.15%
+31,000
New +$1.51M
MASI
98
DELISTED
Masimo
MASI
$1.47M 0.15%
17,000
– –
TSRO
99
DELISTED
TESARO, Inc.
TSRO
$1.42M 0.15%
11,000
-8,000
-42% -$993K
RDUS
100
DELISTED
Radius Health, Inc.
RDUS
$1.41M 0.15%
36,500
– –
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2017 Portfolio in Review

As of Q3 2017, Bellevue Group held 136 positions worth $956M, up 13% from $846M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Bellevue Group deployed $88M of net new capital in Q3 2017, opening 4 new positions and adding to 63 existing holdings. Its largest new stake was Henry Schein: 48,450 shares worth $3.12M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Medtronic, an estimated $7.35M trimmed.

  • Bellevue Group's largest Q3 2017 buy was Henry Schein: 48,450 shares worth $3.12M.
  • Bellevue Group added most to Illumina in Q3 2017, an estimated $10.5M increase.
  • Bellevue Group's biggest Q3 2017 reduction was Medtronic, cutting an estimated $7.35M.
  • Bellevue Group fully exited China Biologic Products Holdings, Inc. in Q3 2017, selling an estimated $4.1M.
  • Bellevue Group's ten largest holdings make up 34% of its $956M portfolio in Q3 2017.
  • Bellevue Group opened 4 new positions and closed 5 in Q3 2017.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $956M.

Based on Bellevue Group's 13F filing for Q3 2017, filed 13 Nov 2017.